Skip to main content
. 2021 Aug 28;13:1759720X211041854. doi: 10.1177/1759720X211041854

Figure 1.

Figure 1.

Summary of (a) ASAS20 response in MEASURE 2 and (b) ASAS40 response in PREVENT at week 16, week 52 and week 260 (MEASURE 2 only).23,33,36 MEASURE 2: Data presented using non-responder imputation at weeks 16 and 52 in the overall population of patients with r-axSpA; presented as observed at week 260 in the overall population. Week 16: secukinumab 150 mg, n = 72; placebo, n = 74. Week 52: secukinumab 150 mg, n = 72. Week 260: secukinumab 150 mg, n = 54. The primary endpoint of MEASURE 2 was the proportion of patients who achieved ASAS20 at week 16 in the overall population. PREVENT: Data presented using non-responder imputation through to week 52 in the TNFi-naïve population of patients with nr-axSpA. Secukinumab 150 mg LD, n = 164; secukinumab 150 mg NL, n = 166; placebo, n = 171. The co-primary endpoints of PREVENT were the proportion of patients in the anti-TNF-naïve population who achieved ASAS40 at weeks 16 (loading dose) and 52 (non-loading dose).

ASAS, Assessment of SpondyloArthritis International Society; LD, loading dose; NL, non-loading dose; nr-axSpA, non-radiographic axial spondyloarthritis; r-axSpA, radiographic axial spondyloarthritis; TNF, tumour necrosis factor; TNFi, tumour necrosis factor inhibitor.